TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24905063
Drug: Estradiol, progestin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol, progestin, and testosterone therapy
Study: 22395196
Drug: Nesiritide group
Normalized name: nesiritide
DrugBank: Nesiritide (DB04899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nesiritide group (received conventional treatment plus nesiritide infusion at 0.0075-0.015 μg·kg(‐1)·min(‐1) for 10-15 hours, total 0.5-1.0 mg once daily for 13 days)
Study: 22395196
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (received only conventional treatment for AHF)
Study: 20089489
Drug: Losartan 0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 0.7 to 1.4 mg/kg per day
Study: 20089489
Drug: Amlodipine 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 0.1 to 0.2 mg/kg per day up to 5 mg/d
Study: 10363572
Drug: Bovine lactoferrin
Normalized name: Bovine lactoferrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine lactoferrin (1.8 or 3.6 g/day)
Study: 7727768
Drug: Low-dose combination
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose combination (ZDV 150 mg and ddl 134 mg, daily)
Study: 7727768
Drug: Moderate-dose combination
Normalized name: Corticosteroids, moderately potent, other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-dose combination (ZDV 300 mg and ddl 334 mg, daily)
Study: 7727768
Drug: High-dose combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose combination (ZDV 600 mg and ddl 500 mg, daily)
Study: 7727768
Drug: ddl monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ddl monotherapy (ddl 500 mg, daily)
Study: 7727768
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment arms combined
Study: 2201495
Drug: Max EPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Max EPA fish oil supplement (15 capsules/day with meals)
Study: 17188087
Drug: 2.5% talactoferrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5% talactoferrin gel
Study: 17188087
Drug: 8.5% talactoferrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8.5% talactoferrin gel
Study: 15536575
Drug: Study solution
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study solution (2 mg of morphine, 15 mg of bupivacaine, 80 mg of methylprednisolone, and 0.05 mg of adrenaline)
Study: 10767223
Drug: Montelukast alone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast alone, 10 mg (ML(10))
Study: 10767223
Drug: Inhaled salmeterol
Normalized name: salmeterol Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled salmeterol alone, 50 microg (SM(50))
Study: 10767223
Drug: Montelukast (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (10 mg) and salmeterol (50 microg)
Study: 10767223
Drug: Montelukast (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (10 mg) and inhaled salmeterol, 100 microg (SM(100))
Study: 10767223
Drug: Placebo inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo inhaler and tablet
Study: 10767223
Drug: Combination therapies
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapies vs ML(10) alone
Study: 2942886
Drug: PCNG (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCNG (30 mg applied 30 minutes before induction)
Study: 31697801
Drug: Emicizumab 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emicizumab 1.5 mg/kg weekly (group A)
Study: 31697801
Drug: Emicizumab 3
Normalized name: Emicizumab 30 mg/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emicizumab 3 mg/kg every 2 weeks (group B)
Study: 31697801
Drug: Emicizumab 6
Normalized name: EMICIZUMAB 60 mg in 0.4 mL SUBCUTANEOUS INJECTION, SOLUTION [Hemlibra]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emicizumab 6 mg/kg every 4 weeks (group C)
Study: 28148685
Drug: Relative iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relative iron bioavailability from 57FePP+ZnSO4
Study: 28148685
Drug: Relative iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relative iron bioavailability from 57FePP-Zn
Study: 28148685
Drug: Relative iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relative iron bioavailability from 57FePP+ZnO
Study: 25856686
Drug: Enoxaparin 1
Normalized name: ENOXAPARIN 100MG/ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 1 mg/kg subcutaneously every 12 hours
Study: 25856686
Drug: Enoxaparin 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 1.5 mg/kg subcutaneously every 24 hours
Study: 10485504
Drug: lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lansoprazole 30 mg/d
Study: 11519776
Drug: rabeprazole 20
Normalized name: RABEprazole 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: rabeprazole 20 mg/d
Study: 11519776
Drug: pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: pantoprazole 40 mg/d
Study: 9710365
Drug: Acarbose 100
Normalized name: acarbose 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose 100 mg for 3 months
Study: 7986182
Drug: Subcutaneously administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneously administered sumatriptan succinate
Study: 7986182
Drug: Second injection
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second injection of subcutaneously administered sumatriptan succinate
Study: 31900579
Drug: Caffeine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (3 mg/kg/day for 20 days)
Study: 28898870
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 buccal spray 800 IU/daily
Study: 28898870
Drug: Oral drops
Normalized name: Oral Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral drops 750 IU/daily
Study: 26347918
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further invasive treatment after primary PCI of the infarct-related artery only
Study: 23832582
Drug: GSK1995057 intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1995057 intravenous infusion (0.0004, 0.002, and 0.01 mg/kg)
Study: 23832582
Drug: GSK1995057 intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1995057 intravenous infusion
Study: 17074624
Drug: Single steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single steroid injection
Study: 14872153
Drug: Genomic medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genomic medicine and candidate single nucleotide polymorphisms
Study: 11696141
Drug: High-dose fentanyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose fentanyl by bolus technique (Group 1, n=8)
Study: 11696141
Drug: High-dose fentanyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose fentanyl by continuous infusion (Group 2, n=6)
Study: 11696141
Drug: Fentanyl-midazolam infusion
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl-midazolam infusion (Group 3, n=5)
Study: 9140018
Drug: S-20098 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-20098 (5 mg)
Study: 9140018
Drug: S-20098 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-20098 (100 mg)
Study: 31540747
Drug: Treatment planning
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment planning designs based on MA.20, EORTC, AMAROS and Z0011 trials
Study: 31540747
Drug: None of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: None of the treatment plan designs
Study: 31383427
Drug: No-treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment group (control group)
Study: 28575729
Drug: Saxagliptin 5mg
Normalized name: Saxagliptin 5mg Oral tablet
DrugBank: Saxagliptin (DB06335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saxagliptin 5mg daily (S5 group)
Study: 28575729
Drug: Metformin 1500mg
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin 1500mg daily (Met group)
Study: 24649781
Drug: 0.5% lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5% lidocaine (10 ml bolus)
Study: 14649215
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy as an adjunct treatment for cardiovascular disease
Study: 14649215
Drug: Improved hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Improved hormone formulations and selective estrogen receptor modulators
Study: 14649215
Drug: Understanding of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Understanding of estrogen receptors in vascular tissue
Study: 14649215
Drug: Timing and
Normalized name: norgestimate and ethinylestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timing and dosing for therapeutic intervention
Study: 10397660
Drug: High-dose fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose fluticasone propionate (100 microg per nostril) 4 times daily for 6 days
Study: 7746690
Drug: Trivalent oral
Normalized name: poliovirus vaccine, live, trivalent oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent oral poliovirus vaccine (3 doses at 2, 3, and 4 months)
Study: 7746690
Drug: Trivalent oral
Normalized name: poliovirus vaccine, live, trivalent oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent oral poliovirus vaccine (2 doses with shorter interval)
Study: 1772001
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of dipyridamole 75 mg t.i.d and acetylsalicylic acid 330 mg t.i.d.
Study: 7042360
Drug: Indoprofen (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indoprofen (200 mg t.i.d.)
Study: 28652278
Drug: Palbociclib (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palbociclib (125 mg/day orally, 3 weeks on, 1 week off) + Fulvestrant (500 mg) + Goserelin
Study: 28652278
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + Fulvestrant (500 mg) + Goserelin
Study: 23135760
Drug: ITF prebiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: ITF prebiotics (inulin/oligofructose 50/50 mix; 16 g/day for 3 months)
Study: 22112039
Drug: HEMA-free one-step
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: HEMA-free one-step adhesive G-Bond (GC)
Study: 17973945
Drug: simvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: simvastatin (40 mg/day)
Study: 18072016
Drug: combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination of ezetimibe and simvastatin
Study: 16025262
Drug: Amifostine 740
Normalized name: Amifostine
DrugBank: Amifostine (DB01143)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amifostine 740 mg/m2
Study: 9092413
Drug: Specific inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific inhibitors (integrelin, lamifiban, tirofiban)
Study: 1788581
Drug: Droperidol 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol 0.25 mg
Study: 6119998
Drug: Neostigmine (0.011
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine (0.011 mg kg‐1)
Study: 6119998
Drug: Neostigmine (0.010
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine (0.010 mg kg‐1)
Study: 26452447
Drug: Tadalafil 5
Normalized name: tadalafil 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 5 mg once-daily
Study: 19686113
Drug: 0.5% (w/w)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% (w/w) monosodium L-glutamate (MSG) added to rice gruel, 3 times a day for 3 months
Study: 19686113
Drug: 0.5% (w/w)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% (w/w) monosodium L-glutamate (MSG)
Study: 7895928
Drug: Omeprazole (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (8 mg/h after a bolus of 80 mg)
Study: 7895928
Drug: Omeprazole (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (4 mg/h after a bolus of 80 mg)
Study: 7895928
Drug: Ranitidine (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (0.25 mg/kg/h after a bolus of 50 mg)
Study: 31582549
Drug: No Granulocyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Granulocyte colony-stimulating factor (non-G-CSF)
Study: 17212913
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (laminectomy)
Study: 31434781
Drug: Non-surgical treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical treatment (structured physical training programme)
Study: 23220856
Drug: Remifentanil dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil dosage adjusted according to SPI
Study: 21669894
Drug: Sucrose plus
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucrose plus EMLA cream (S+E group)
Study: 21669894
Drug: Sucrose plus
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucrose plus placebo cream (S group)
Study: 3956275
Drug: Cimetidine (H2-antagonist)
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine (H2-antagonist)
Study: 31490861
Drug: Early self-directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early self-directed home exercise program (HEP) for 6 weeks with weekly supportive telephone calls
Study: 29717497
Drug: Neutral agent
Normalized name: DentiCare Neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutral agent
Study: 27684290
Drug: Aripiprazole 10
Normalized name: aripiprazole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole 10 mg oral dose
Study: 24515927
Drug: Traditional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional therapy (n = 14)
Study: 18314230
Drug: Diacylglycerol oil
Normalized name: DIACYLGLYCEROL OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diacylglycerol oil (25 g/day for 120 days)
Study: 18314230
Drug: Triacylglycerol oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triacylglycerol oil (25 g/day for 120 days)
Study: 15780649
Drug: Lateral wedge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lateral wedge with subtalar strapping for less than 5 hours daily (short group), n=21
Study: 15780649
Drug: Lateral wedge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lateral wedge with subtalar strapping for 5-10 hours daily (medium group), n=20
Study: 15780649
Drug: Lateral wedge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lateral wedge with subtalar strapping for greater than 10 hours daily (long group), n=18
Study: 12098171
Drug: Valdecoxib (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valdecoxib (40 mg twice a day)
Study: 12098171
Drug: Diclofenac (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac (75 mg twice a day)
Study: 6357892
Drug: Hydrocortisone butyrate
Normalized name: Hydrocortisone Butyrate
DrugBank: Hydrocortisone butyrate (DB14540)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrocortisone butyrate cream 0.1%
Study: 27113290
Drug: Paricalcitol (PCT,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paricalcitol (PCT, 2 μg/day)
Study: 20571804
Drug: 120 kVp
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 kVp and 1.8 ml/kg contrast agent (300 mgI/ml)
Study: 20571804
Drug: 80 kVp
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 kVp and 1.2 ml/kg contrast agent
Study: 18056526
Drug: Prasugrel 10
Normalized name: prasugrel 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 10 mg/d maintenance dose
Study: 18056526
Drug: Clopidogrel 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 150 mg/d maintenance dose
Study: 16096437
Drug: Exemestane (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exemestane (25 mg/day; n=172)
Study: 12404032
Drug: Lornoxicam 8
Normalized name: lornoxicam 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lornoxicam 8 mg/day
Study: 12404032
Drug: Lornoxicam 16
Normalized name: Lornoxicam 16 mg prolonged-release oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lornoxicam 16 mg/day
Study: 7596218
Drug: Epalrestat (aldose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epalrestat (aldose reductase inhibitor), treated for one month
Study: 2164706
Drug: Bovine rotavirus
Normalized name: human-bovine reassortant rotavirus strain G1 vaccine / human-bovine reassortant rotavirus strain G2 vaccine / human-bovine reassortant rotavirus strain G3 vaccine / human-bovine reassortant rotavirus strain G4 vaccine / human-bovine reassortant rotavirus strain P1A[8] vaccine Oral Suspension [RotaTeq]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine rotavirus vaccine RIT 4237
Study: 31811463
Drug: Elosan therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elosan therapy (4-min sessions, twice/week for 28 days)
Study: 31811463
Drug: Elosan therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elosan therapy
Study: 28990439
Drug: Oral fennel
Normalized name: Fennel
DrugBank: Fennel (DB15615)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fennel (n=30)
Study: 25675199
Drug: Lowest homoarginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lowest homoarginine quartile (<1.40 μmol/L)
Study: 19770473
Drug: Telcagepant 50
Normalized name: Telcagepant
DrugBank: Telcagepant (DB12228)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telcagepant 50 mg
Study: 15274426
Drug: Thiopental (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental (25 mg)
Study: 15274426
Drug: Thiopental (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental (50 mg)
Study: 15274426
Drug: Thiopental (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental (75 mg)
Study: 15274426
Drug: Thiopental (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental (100 mg)
Study: 8319654
Drug: Chlorinated water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorinated water (20 ppm, 1.5 L per day)
Study: 3546223
Drug: Pre-treatment transurethral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment transurethral resection (TUR)
Study: 27978579
Drug: Selumetinib 100
Normalized name: Sélumétinib
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selumetinib 100 mg orally per day plus MK-2206 135 mg orally once per week
Study: 27978579
Drug: mFOLFOX (oxaliplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFOLFOX (oxaliplatin 85 mg/m2 intravenous and fluorouracil 2400 mg/m2 intravenous infusion over 46-48 hours)
Study: 25629634
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (control)
Study: 23948221
Drug: Continuous Positive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Positive Airway Pressure (CPAP) treatment after 6 months
Study: 23948221
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (before CPAP)
Study: 21481064
Drug: Platelet-rich plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich plasma (PRP) applied on one side after FxCR treatment
Study: 16231341
Drug: Group therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group therapy (GRP)
Study: 15078380
Drug: Cardiac Analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac Analgesic Assessment Scale (CAAS)
Study: 10729392
Drug: Low fat
Normalized name: Low fat spread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low fat meal (10 g fat)
Study: 8854774
Drug: Arterial Embolization
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arterial Embolization Chemotherapy (AEC)
Study: 8854774
Drug: Continuous Arterial
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Arterial Infusion Chemotherapy (CAIC)
Study: 1451218
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine sulphate (4 mg in 10 ml saline)
Study: 1451218
Drug: Epidural saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural saline (10 ml saline)
Study: 6091475
Drug: Ceftriaxone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (1 g preoperatively)
Study: 30684970
Drug: Low-dose hCG
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose hCG at the time of GnRH-agonist trigger (Group 1)
Study: 30684970
Drug: Low-dose hCG
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose hCG at the time of oocyte retrieval (Group 2)
Study: 15613414
Drug: Testosterone patches
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone patches
Study: 12296782
Drug: Elyzol Dental
Normalized name: Elyzol
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Elyzol Dental Gel
Study: 6697637
Drug: Carteolol 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carteolol 0.5 to 60 mg daily
Study: 17117002
Drug: Hybrid functional
Normalized name: Amaranthus hybridus pollen
DrugBank: Amaranthus hybridus pollen (DB15503)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid functional electrical stimulation therapy on extensor carpi radialis longus and brevis, extensor digitorum communis, and extensor indicis proprius muscles, once or twice a week for 4 months after motor point blocks at the spastic finger flexor muscles
Study: 15065610
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 440 microg twice daily
Study: 1586175
Drug: Exosurf (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exosurf (2 doses in 24 hours)
Study: 1586175
Drug: Exosurf (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exosurf (4 doses in 36 hours)
Study: 3802303
Drug: Pirenzepine 100
Normalized name: pirenzepine
DrugBank: Pirenzepine (DB00670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine 100 mg/die/p.o.
Study: 3802303
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg/die/p.o.
Study: 27335049
Drug: Crisaborole topical
Normalized name: crisaborole topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crisaborole topical ointment, 2%, applied twice daily for 21 days